Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 161Recurrence 30Neoplasms, Plasma Cell 11Neoplasms 7Lymphoma, Mantle-Cell 7Paraproteinemias 6Lymphoma, Follicular 5Hematologic Neoplasms 5Lymphoma, Non-Hodgkin 4Immunoglobulin Light-chain Amyloidosis 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Immunoproliferative Disorders 3Immune System Diseases 3Hematologic Diseases 3Carcinoma, Non-Small-Cell Lung 3Blood Protein Disorders 3Plasmacytoma 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Lymphoproliferative Disorders 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Acute 2Hemostatic Disorders 2Hemorrhagic Disorders 2Bone Marrow Neoplasms 2Amyloidosis 2Wilms Tumor 1

Interventions

satraplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma, Bronchiolo-Alveolar × Bortezomib × Clear all
NCT00117351 2011-02-17

VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features

Millennium Pharmaceuticals, Inc.

Phase 2 Terminated
Thoracic

Adenocarcinoma, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡